Skip to main content
PLOS One logoLink to PLOS One
. 2020 Aug 11;15(8):e0237083. doi: 10.1371/journal.pone.0237083

Quality of hypertension management in public primary care clinics in Malaysia: An update

Xin Rou Teh 1,*,#, Ming Tsuey Lim 1,#, Seng Fah Tong 2, Masliyana Husin 1, Noraziani Khamis 3, Sheamini Sivasampu 1
Editor: Anderson Saranz Zago4
PMCID: PMC7418969  PMID: 32780769

Abstract

Introduction

Adequate control of hypertension is a global challenge and is the key to reduce cardiovascular disease risk factors. This study evaluates management of hypertensive patients in primary care clinics in Malaysia.

Methods

A cross-sectional analysis of 13 784 medical records from 20 selected public primary care clinics in Malaysia was performed for patients aged ≥30 years old who were diagnosed with hypertension and had at least one visit between 1st November 2016 and 30th June 2019. Multivariable logistic regression adjusted for complex survey design was used to determine the association between process of care and blood pressure (BP) control among the hypertensive patients.

Results

Approximately 50% of hypertensive patients were obese, 38.4% of age ≥65 years old, 71.2% had at least one comorbidity and approximately one-third were on antihypertensive monotherapy. Approximately two-third of the hypertensive patients with diabetic proteinuria were prescribed with the appropriate choice of antihypertensive agents. Approximately half of the patients received at least 70% of the target indicated care and 42.8% had adequately controlled BP. After adjusting for covariates, patients who received counseling on exercise were positively associated with adequate BP control. Conversely, patients who were prescribed with two or more antihypertensive agents were negatively associated with good BP control.

Conclusions

These findings indicated that BP control was suboptimal and deficient in the process of care with consequent gaps in guidelines and actual clinical practices. This warrants a re-evaluation of the current strategies and approaches to improve the quality of hypertension management and ultimately to improve outcome.

Introduction

Hypertension is an important public health challenge as it is associated with higher risk of cardiovascular (CV) and renal diseases [1]. A pooled analysis on worldwide trends in blood pressure (BP) from 1975 to 2015 showed that the number of adults with hypertension had increased from 594 million in 1975 to 1.13 billion in 2015 [2]. As of 2017, hypertension has been identified as the leading risk factor for premature death and disability worldwide [3]. There is an increasing concern that hypertension is becoming more prevalent in low- and middle-income countries than in high income countries [1, 4]. Furthermore, it disproportionately affects populations in low- and middle-income countries with resource constrained health systems [1], thus, achieving optimal BP control is a challenge [5].

The proportion of treated hypertensive patients achieving BP control (<140/90 mm Hg), reviewed ten years ago, were less than 40% in both developed and developing countries [4, 6]. Malaysia like other developing countries is not spared from the alarmingly low rate of BP control among the treated hypertensive patients. The National Health and Morbidity Survey for non-communicable disease risk factors from 2006 to 2015 showed that more than 75% of the hypertensive patients were on antihypertensive treatments [7]. Despite the high proportion of patients received treatment over time, the overall BP control (<140/90 mmHg) was 27.5% in 2006, 34.3% in 2011 and 37.4% in 2015 [7]. In essence, hypertension control in Malaysia still remains inadequate.

One of the possible causes for poor hypertension control could be due to suboptimal quality of hypertension care provided to the patients [811]. It was observed that patients who received optimal hypertensive care were more likely to have better BP control [8, 10]. The quality of hypertensive care provided can be assessed by conducting essential care processes received by medical record extraction. This step also includes monitoring of the process of care which are closely related to CV risks such as BP and low-density lipoprotein-cholesterol levels. The selected process measures are usually evaluated against a standard set of criteria as recommended by hypertension management guidelines which include concise evidence-based recommendation to prescribers that have been regularly updated, published and disseminated.

A large majority of hypertensive patients receive their care in primary care setting in Malaysia [12]. A strong coordinating role of primary care is essential to ensure adequate coordination of patient care between primary care providers, as well as coordination of patient care between primary care and other levels of health care to cope with the demand for long term care arrangements. This is of critical importance as evidence has shown that patients with chronic conditions including hypertension are better managed in primary care and this could reduce avoidable hospitalization rates [13].

In Malaysia, improvement in process of care has been undertaken over the years with better establishment of non-communicable disease care such chronic care concepts, diabetic registry, nurse educator and better range of antihypertensive medication. Although there were some evaluations on hypertension, process of care evaluation was last done 10 years ago [11]. Most of the evaluations on hypertensive care focused on the burden of hypertension in the Malaysian population [1416]. Similarly, evaluations on process of care and BP control in low- and middle-income countries are scarce. Therefore, we aimed to evaluate the current process of care for hypertension management as well as to explore the association between process of care and BP control among hypertensive patients in public primary care clinics in Malaysia.

Materials and methods

Study design, population and sampling

Ethical approval was granted by the Medical Research and Ethics Committee, Ministry of Health Malaysia (NMRR-17-267-34768). Waiver of consent was obtained as medical records were reviewed retrospectively. All records were anonymized before use in the analysis.

Malaysia has a dual tiered healthcare system consisting of government-led and funded public sector as well as private sector with charges fee-for-service. This study focused on the public sector because hypertension was largely managed in this healthcare setting [12]. The evaluation was undertaken based on part of a larger study entitled “Evaluation of the Enhanced Primary Healthcare (EnPHC) interventions in public health clinics” (EnPHC-EVA: Facility). At the point of writing, the study protocol of EnPHC-EVA: Facility is under journal review. The EnPHC-EVA: Facility was a quasi-experimental controlled study which assessed the effectiveness of EnPHC intervention package on process of care and intermediate clinical outcomes for type 2 diabetes mellitus (T2DM) and hypertension across 40 public health clinics located in Malaysia. The criteria to match the 40 selected clinics were i) mean daily attendances ii) the number of medical doctors and family medicine specialists iii) geographical location (urban or rural) and iv) the availability of electronic medical records. As a result, 20 matched pairs were acquired and each clinic within the pairs was randomly assigned to either intervention or control arm using a coin flipping method.

The present analysis utilised the data from patients’ medical records in the control clinics reviewed between 1st November 2016 and 30th June 2019. The inclusion criteria were the medical records of all patients aged 30 years and above, diagnosed with hypertension and had at least one visit during the study period. Pregnancy induced hypertension were excluded since their disease management was different. A systematic random sampling was used to sample the patients’ medical records in the clinics. Data such as patients’ demographic and clinical characteristics were extracted into the electronic structured data collection form using a mobile tablet with validation rules to ensure validity.

Measures

The measurements of interest were 1) process of care and 2) prescribing practice for hypertensive patients. The process of care included documentation of patients’ physical examinations such as systolic BP and diastolic BP, weight, height, waist circumference, body mass index (BMI), electrocardiography test and fundus examinations. Laboratory investigations including blood glucose, serum creatinine, fasting lipid profile, and urinalysis for microalbuminuria were extracted. All physical examinations and laboratory investigations done within the past one year were considered with the exception of weight and BMI measured within past six months as well as BP assessed at the current visit for better accuracy. In addition, process of care on CV risk assessment such as Framingham Risk Score performed in the past one year and types of counseling provided were recorded. Types of counseling extracted included counseling on diet education, exercise/physical activity, smoking cessation, salt intake and alcohol intake. Data on prescription were also extracted which included the types and number of antihypertensive agents. The antihypertensive agents prescribed were categorized into i) one drug, ii) two drugs and iii) ≥ three drugs. Those without anti-hypertensive agents prescribed but with a diagnosis of hypertension were considered to be on lifestyle modification. The process of care and the prescribing practices that were not documented will be interpreted as “not done” even though the patient may indeed receive the care in actuality [17].

In this study, “controlled hypertension” is defined as having BP <140/90 mmHg (for hypertensive patients without any comorbidity), BP <140/80 mmHg (for diabetic hypertensive patients), BP <130/80 mmHg (for hypertensive patients with ischaemic heart disease /cerebrovascular disease/renal impairment) and BP <150/90 mmHg (for patients aged 80 years and above) as defined by our Malaysian Clinical Practice Guidelines (CPG) on Hypertension 2018 [18]. Patients were categorised as obese and non-obese using cut-off point 27.5 kg/m2 according to the World Health Organisation BMI criteria for Asians [19]. Those antihypertensive drugs that were prescribed not according to criteria set in the Malaysian CPG on Hypertension 2018 were considered as inappropriate choice of antihypertensive agents [18]. These drugs were considered inappropriate choice if any of the following was fulfilled: i) alpha-blocker was prescribed as a single agent to hypertensive patients with T2DM or elderly patients ≥ 65 years old ii) beta-blocker was prescribed as a single agent to hypertensive patients with T2DM or dyslipidemia, iii) diuretic was prescribed as a single agent for hypertensive patients with T2DM or dyslipidemia, iv) angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) was not prescribed to T2DM patients with proteinuria.

Statistical analysis

Continuous variables were presented as mean and standard deviation while categorical variables were reported in frequencies and percentages. Multivariable logistic regression using complex survey design to account for clustering effect within clinics was used to estimate the adjusted odds ratio and 95% confidence interval for the association of process of care and prescribing practice on BP control. Complete case analysis was performed for the regression. The process of care variables included in the regression were documentation of BMI, electrocardiography, funduscopy, fasting/random blood glucose, creatinine, low-density lipoprotein-cholesterol, urine albumin, Framingham Risk Score, smoking cessation counseling, diet education counseling, salt intake counseling, alcohol intake counseling, and exercise/physical activity counseling. The variable used for prescribing practice was number of antihypertensive agents prescribed. Covariates included for adjustment were age, gender, ethnicity, the number of comorbidities, obesity, the location of primary care clinic and duration of hypertension. Multicollinearity of the covariates was checked. This was a cross sectional study on hypertension management, thus we could not include dropouts and compliance as our covariates. A p-value of <0.05 was considered as statistically significant. Data were analysed using Stata version 14.3 [20].

Results

Overall, a total of 13 784 patient medical records were reviewed (Table 1). The mean age was 61.0 years, ranging between 30 to 97 years of age. The majority were women (60.4%) and of Malay ethnicity (66.0%) which reflects the local demographic profile. Approximately 50% of hypertensive patients were obese, 38.4% of age ≥65 years old, more than two-third had at least one comorbidity and less than 50% had adequately controlled BP.

Table 1. Patient demographic data.

Characteristic n(%)
Mean age, years (SD) 61.0(11.1)
Age group (years)
 <65 8487(61.6)
 ≥ 65 5297(38.4)
Gender
 Female 8322(60.4)
 Male 5462(39.6)
Ethnicity
 Malay 9098(66.0)
 Chinese 3188(23.1)
 Indian 1298(9.4)
 Others 200(1.5)
Location of primary care setting
 Urban 7988(58.0)
 Rural 5796(42.0)
Obesity (n = 10 400)
 BMI <27.5 kg/m2 5215(50.1)
 BMI ≥27.5 kg/m2 5185(49.9)
Comorbidity
 T2DM 6901(50.1)
 Dyslipidaemia 6643(48.2)
 Chronic Kidney Disease 1408(10.2)
 Ischaemic heart disease 918(6.7)
 Stroke/Transient Ischaemic Attack 583(4.2)
 Heart failure 205(1.5)
Number of co-morbidities
 0 3968(28.8)
 1 4576(33.2)
 ≥2 5240(38.0)
Mean duration of hypertension, years (SD)
(n = 13 783) 7.0(6.0)
BP Status (Overall)
 Controlled 5903(42.8)
 Uncontrolled 7881(57.2)

If n is not stated, the total patients included in the analysis was 13 784.

SD standard deviation, BMI body mass index, BP blood pressure, T2DM type 2 diabetes mellitus

Table 2 shows the proportion of documented process of care received by the hypertensive patients. Half of process of care for physical examination and laboratory investigation had at least 70% of the clinical parameters documented. Nevertheless, almost all the records had BP readings on visit date. The laboratory findings indicated a lower proportion of the patients had documentation of low-density lipoprotein–cholesterol and high-density lipoprotein–cholesterol compared to total cholesterol and triglyceride level. Unfortunately, less than one percent of the records had documented CV risk assessment. Non-pharmacological management including counseling on cessation of smoking, salt intake and alcohol consumption were observed in less than 20% of the records.

Table 2. Process of care for hypertensive patients.

Process of care n(%)
Documented Physical examination
SBP reading in the current visit 13 674(99.2)
DBP reading in the current visit 13 674(99.2)
Weight measurement in the past 6 months 11 978(86.9)
Height measurement 10 944(79.4)
Waist circumference measurement 8220(59.6)
ECG in the past 1 year (n = 13 454) 5669(42.1)
BMI measurement in the past 6 months 5227(37.9)
Funduscopy in the past 1 year (n = 13 545)
  With T2DM (n = 6680) 2274 (34.0)
  Without T2DM (n = 6865) 136 (2.0)
Documented laboratory investigation in the past 1 year
Blood glucose
  Fasting/random blood glucose 11 985(86.9)
Renal profile
  Creatinine 11 448(83.1)
Fasting lipid profile
  Total cholesterol 11 165(81.0)
  Triglycerides 11 072(80.3)
  HDL cholesterol 9201(66.8)
  LDL cholesterol 9061(65.7)
Urine test
  Urine albumin (n = 13 689) 8095(59.1)
CV risk assessment in the past 1 year 111(0.8)
Counseling
  Diet education 5998(43.5)
  Exercise/Physical activity 4512(32.7)
  Smoking cessation (n = 10 161) 1144(11.3)
  Salt intake 1093(7.9)
  Alcohol intake (n = 11 775) 384(3.3)

If n is not stated, the total patients included in the analysis was 13 784.

SBP systolic blood pressure, DBP diastolic blood pressure, ECG Electrocardiogram, BMI body mass index, LDL low-density lipoprotein, HDL high-density lipoprotein, T2DM type 2 diabetes mellitus, CV cardiovascular

The rate of BP control was lower among the hypertensive patients with comorbidities compared to hypertensives alone (Table 3). Hypertensive patients with lifestyle modification appeared to have a better BP control rate compared to those on antihypertensive agents.

Table 3. Blood pressure control status in different subgroups of hypertensive patients.

BP Status by group as per CPG 2018 n(%)
HPT with antihypertensive agents (n = 13446)
 Controlled 5732(42.6)
 Uncontrolled 7714(57.4)
HPT on lifestyle modification (n = 338)
 Controlled 171(50.6)
 Uncontrolled 167(49.4)
HPT without comorbidity and ≤ 80 years (n = 5831)
 Controlled 3178(54.5)
 Uncontrolled 2653(45.5)
HPT with T2DM (n = 4970)
 Controlled 1751(35.2)
 Uncontrolled 3219(64.8)
HPT with CKD/IHD/Stroke/TIA (n = 2466)
 Controlled 591(24.0)
 Uncontrolled 1875(76.0)
Age > 80 years (n = 517)
 Controlled 383(74.1)
 Uncontrolled 134(25.9)

If n is not stated, the total patients included in the analysis was 13 784.

SD standard deviation, CPG clinical practice guidelines, BMI body mass index, BP blood pressure, TIA transient ischaemic attack, IHD ischaemic heart disease, CKD chronic kidney disease, HPT hypertension, T2DM type 2 diabetes mellitus

Overall, 97.5% of the hypertensive patients were prescribed antihypertensive drugs while the remaining (2.5%) were on lifestyle modification (Table 4). Approximately two-third of the hypertensive patients were on two or more types of antihypertensive agents. When all cases of monotherapy and the combination of two or more antihypertensive agents were considered together, calcium channel blockers (CCBs) (77.2%) were the most commonly prescribed followed by ACEIs (54.8%), beta blockers (29.8%), diuretics (23.4%), ARBs (5.8%) and alpha-blockers (4.6%). Almost all the patients (>98%) with comorbidities were prescribed with the appropriate choice of antihypertensive agents except for hypertensive diabetic patients with proteinuria in which less than 70% were prescribed with ACEI or ARB.

Table 4. Prescribing pattern of antihypertensive agents.

Antihypertensive agents prescribed Total, n(%) BP status, n(%)
Controlled Uncontrolled
Number of antihypertensive agents prescribed 5903 7881
 0 338(2.5) 171(2.9) 167(2.1)
 1 4994(36.2) 2535(42.9) 2459(31.2)
 2 5030(36.5) 2102(35.6) 2928 (37.2)
 ≥ 3 3422(24.8) 1095(18.5) 2327 (29.5)
Type antihypertensive agents (n = 13 446) 5732 7714
 CCB 10 382(77.2) 4363(76.1) 6019(78.0)
 ACEI 7363(54.8) 2754(48.0) 4609(59.7)
 Beta-blocker 4002(29.8) 1519(26.5) 2483(32.2)
 Diuretics 3152(23.4) 1166(20.3) 1986(25.7)
 ARB 782(5.8) 300(5.2) 482(6.2)
 Alpha-blocker 623(4.6) 196(3.4) 427(5.5)
Inappropriate choice of antihypertensive agents
Alpha-blocker as single agent among
  T2DM patients (n = 6883) 5(0.1) 4(0.2) 1(0.0)
  Elderly (age ≥65 years) patients (n = 5276) 6(0.1) 4(0.2)
2(0.1)
Beta-blocker as single agent among
  T2DM patients (n = 6883) 101(1.5) 40(1.8) 61(1.3)
  Dyslipidaemia (n = 6624) 125(1.9) 63(2.3) 62(1.6)
Diuretics as single agent among
  T2DM patients (n = 6883) 53(0.8) 26(1.1) 27(0.6)
  Dyslipidemia (n = 6624) 56(0.8) 29(1.0) 27(0.7)
ACEI or ARB not prescribed for T2DM patients with proteinuria (n = 3475) 1135(32.7) 493(40.0) 642(28.6)

If n is not stated, the total patients included in the analysis was 13 784.

ACEI Angiotensin converting enzyme inhibitor, ARB Angiotensin receptor blocker, CCB Calcium channel blocker, T2DM type 2 diabetes mellitus.

Fig 1 shows the results of multivariable logistic regression analysis which explored the factors associated with BP control. After adjusting for covariates, counseling on exercise was shown to positively associated with BP control (OR 1.31, 95% CI 1.04–1.63). Conversely, hypertensive patients who were prescribed with two or more antihypertensive agents were negatively associated with BP control.

Fig 1. Adjusted ORs with corresponding 95% CI for factors associated with BP control.

Fig 1

OR odds ratio, CI confidence interval, BP blood pressure. † Adjusted for age, gender, ethnicity, number of comorbidities, obesity, location of primary care clinic (urban or rural) and duration of hypertension. *p<0.05.

Discussion

To the best of our knowledge, our study is the first to report on documented process of care for hypertension involving multiple centres in Malaysia using patient medical records. In this study, documentation in patient medical records were used as a proxy to describe the process of care in hypertension management. Overall, approximately 43% of hypertensive patients in this study had adequately controlled BP. The rate of BP control was lower among the hypertensive patients with comorbidities compared to hypertensive alone. The process of care received by the hypertensive patients were suboptimal as more than 50% of them did not receive the process of care that were recommended by the local guideline. A substantial proportion of the hypertensive patients with diabetic proteinuria was not prescribed as per CPG [18]. The results showed that counseling on physical exercise was associated with better BP control rate whereas higher number of medications used was associated with worse BP control rate.

The overall BP control in this study is comparable to that of previous local studies at primary care setting [21, 22]. This showed that there has not been much improvement in the overall BP control rate despite the advancement in process of care arising from the amelioration in care structure in Malaysian public primary care clinics over the years. This includes the availability of trained family physicians, diabetes registry, non-communicable disease units in the clinics, improved laboratory service in the clinic for chronic disease management and availability of a wide range of anti-hypertensives [12, 2326]. A local study reported that there was an increasing trend in the percentage of documented investigations conducted for evaluation of hypertension during a patient’s first clinic visit from 1998 to 2012 [17]. Apart from this, the Malaysian Statistics on Medicines report revealed that there was substantial increase in utilisation pattern of certain antihypertensive classes in the public primary care clinics [25]. In terms of prescribing pattern, CCBs were the most prescribed class of antihypertensive followed by ACEIs, beta blockers and diuretics from 2011 to 2014 [25]. Similar antihypertensive prescribing trend was also observed in this study. The high utilisation of CCBs especially amlodipine was due to the removal of prescribing restriction in the Ministry of Health Malaysia formulary as well as the introduction of generic amlodipine in the public primary care clinics [27]. In addition, beta-blockers which were once recommended as the first-line treatment for hypertension was later superseded by other classes of antihypertensive drugs [18]. Thus, the possible factors contributing to suboptimal control of hypertension could be due to patient-related factors including patients’ lifestyle and other risk factors, difficulties in adherence to prescribed regimens, limited access to care and lack of knowledge about seriousness of hypertension. It can also be influenced by healthcare provider-related factor such as effectiveness of counseling on lifestyle factors and self-care [2830]. The suboptimal coordination of hypertension care that were received by our patients may be another possible cause for the poor BP control. Although the Chronic Care Model [31] has provided the structure needed for managing chronic disease such as hypertension, the effective implementation still requires optimal coordination, consultation, counseling and good communication skills. However, these need to be evaluated in future studies.

With regards to suboptimal process of care based on the CPG [18], the fact that almost all hypertensive patients did not receive complete CV risk assessment is of great concern. The incomplete or inadequate assessment of CV risk factors may result in missed opportunities for early intervention and pose a negative impact on the morbidity and mortality of the patients. A decrease in these CV risk factors has been shown to reduce CV morbidity and mortality in both individuals with or without established CV disease [32]. Furthermore, the data from the National Health and Morbidity Surveys of Malaysia in 2015 [7] indicated that the prevalence of CV risk factors including hypertension, dyslipidaemia, T2DM, overweight or obesity and smoking is high and has been on an increasing trend. The possible causes for the poor rate of compliance to guidelines or the practice gap for the CV risk assessment were reported to be the absolute lack of physician time [33], knowledge-related factors such as lack of awareness, clinical experience and familiarity or attitude-related factors including lack of agreement, lack of outcome expectancy, self-efficacy, and motivation [29]. Nevertheless, important CV risk such as documentation of investigation on fasting blood glucose, cholesterol profile, renal function, BP status in this study were well documented.

Another important finding worth noting is that adequacy rate of fundoscopy was similarly observed in a previous local clinical audit on hypertensive care [9]. This indicated that a high proportion of the hypertensive patients with T2DM have not undergone regular eye examinations in the primary care clinics as recommended by clinical guidelines [34]. Regular eye examination is essential since early detection and treatment of eye diseases including retinopathy considerably reduce the incidence of blindness. This is because early retinopathy tends to be unnoticeable by patients due to the absence of visual loss in the early stage. In fact, retinopathy is the most common microvascular complication of diabetes mellitus [35]. A study by Erden et al. (2012), indicated that the increase in the incidence of retinopathy is related to the degree of severity and duration of hypertension [36]. The low percentage of patients who had undergone fundus examinations seen may contributed by the lack of awareness among healthcare providers on the needs for eye screening, non-adherence to the guideline, patients defaulting on follow-up examinations, overcrowding at public health clinics or healthcare provider not proficient on the use of direct ophthalmoscopes to examine the fundus or patients' refusal for pupil dilatation [9].

Our findings suggest that there is a large gap between guidelines and actual clinical practices when pharmacological treatment is concerned. Approximately 30% of the diabetic patients with proteinuria were not prescribed with the recommended ACEI or ARB where these antihypertensive classes are the first line treatment options in the absence of any other contraindications [18]. Though there could be valid reasons including cost, side-effects and patient preference for not prescribing ACEI or ARB, the 30% of non-adherence to CPG [18] may be too high to be accountable for by these factors. The medication adherence to guideline issue was also earlier reported in other local studies conducted in primary care settings [22, 28, 30]. For example, according to Cabana et al. (1999), doctors’ intentions to use the guidelines can be predicted from their attitudes towards the guidelines, which are influenced by many factors including their own knowledge, past clinical experience, beliefs and adherence to guidelines, outcome expectations, peers’ opinions as well as external barriers including patient’s characteristics and environmental factors [29]. Therefore, remedial measures should be taken to allow better promotion and adoption of practice guidelines into daily practice of the doctors in the primary care clinics.

Our findings indicate that hypertensive patients who had documented counseling on exercise/physical activity had 1.3 odds of having their BP controlled compared to those not receiving counseling. However, the information on how counseling was performed was not available in the medical record. We assume that the counseling was done as the usual practice in the clinic. The association of exercise/physical activity with lower BP was also reported in a previous study [37]. Aside from giving more exercise prescriptions, doctors may encourage the patients to be more active including walking, using bicycles, climbing stairs or pursuing other means of integrating physical activity into their daily routines. Furthermore, exercise prescription can also be used to manage the obese hypertensive patients. A previous study [38] reported that the obese tend to benefit from a regular exercise regimen in terms of having an improved insulin sensitivity, better lipid and lipoprotein profile, BP as well as a reduced risk of death. Exercise therapy should be performed in lieu with diet therapy to improve obesity. Surprisingly, in this study, no association between counseling on salt intake and good BP control was observed. These findings suggest that counseling on salt intake, although documented, may not be received by patients effectively. Nevertheless, this type of counseling is essential as a study [39] has shown that reduction of salt intake can reduce BP and decrease the need for medications in patients who are “salt sensitive” where BP fluctuations are highly dependent on the level of sodium intake.

In this study, approximately two-third of the hypertensive patients who are on combination therapy still have poor BP control. Conversely, we found that hypertensive patients who have been prescribed with a combination therapy of antihypertensive agents are more likely to have poor BP control. Similar finding was also observed in a previous local study conducted on hypertensive control among hypertensive patients with T2DM in primary care clinics [21]. This unexpected finding is in contrast with the literature where it has been reported that combination of antihypertensive drugs from different classes have additive or synergistic effects when used together, whereby the reduction in BP is greater than if patients were treated with either drug class alone [40]. It is plausible that patients who are on combination therapy were the subgroup of those who had more resistant BPs or may even have underlying secondary hypertension or there was a failure of physicians to increase the dose, number of antihypertensive agents or change the treatments [21, 41]. Additionally, treating to target with clear agreed target BP may pose as a challenge since disagreement of dosing and number of medications between patients and doctors often occur. This will also contribute to non-adherence and suboptimal BP control.

The major strength of the study is the large sample of patients which allowed sufficient statistical power to explore how the care processes of hypertension affect BP control among hypertensive patients. Another strength was that the study was conducted across 20 chosen primary care clinics which are representative of the public clinics in Malaysia. There were some limitations in this study. First, the cross-sectional study design cannot be used to establish causal and effect relationship between the factors and outcome. Second, since it is a record-based study, we did not have some of the patients’ information including the level of education, occupation or socioeconomic status which may influence patients’ self-management such as medication adherence or compliance to lifestyle intervention to a certain extent. Third, the information on counseling was limited to type of counseling documented in the medical records. It would be difficult to capture the effectiveness of counseling given to the patients during the doctor-patient consultation session. Thus, we assumed that counseling was delivered accordingly by the attending primary care doctors. Similarly, information on the dose and duration of the antihypertensive agents were not extracted because it was assumed that the dose titration process will occur over time, aiming at BP control. Hence, it is not feasible to measure antihypertensive medication titration on BP control with our cross-sectional study design. Fourth, the assumption of the process of care and prescribing practices not documented in the medical records are considered as not done and may underestimate the actual quality of care received by the patients. Lastly, the findings cannot be generalizable to the private clinics since the study population was solely from public health clinics.

Conclusion

Our present findings show that BP control was suboptimal in public primary care clinics. The process of care remains deficient with gaps in guidelines and actual clinical practice. These suboptimal BP control and hypertensive management findings were consistent with several local cross-sectional surveys and clinical audits on hypertension management conducted in primary care [7, 9, 11, 17, 21, 22, 28, 30]. These consistent findings as previous studies demonstrated that the hypertensive care in Malaysia still remains much as it was in the past decade. Therefore, a continuous and concerted efforts are warranted to improve the quality of hypertensive management. Apart from looking at traditional issues of physician awareness of hypertension and physician adherence to guidelines, an evaluation on the how the process being undertaken is important in order for us to understand the dynamics within a primary care clinic.

Acknowledgments

The authors would like to thank the Director General of Health Malaysia for the permission to publish this paper. We would also like to thank the patients and health providers who participated in the EnPHC-EVA: Facility study as well as the EnPHC-EVA: Facility study investigators.

Data Availability

All relevant data are provided within the manuscript. Individual level data cannot be made publicly available due to ethical and patient confidentiality restrictions. The data collected within this study is managed in accordance with the Personal Data Protection Act in Malaysia and is subject to ethical restrictions under the Medical Research and Ethics Committee, Ministry of Health Malaysia. Data is available on request and interested researchers may address data access requests to the Institute for Clinical Research at contact@crc.gov.my.

Funding Statement

This study was supported by a grant from the Ministry of Health, Malaysia (NMRR-17-267-34768) under the Malaysian Health Systems Research initiative. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.World Health Organization. A Global Brief on Hypertension. Silent Killer, Global Public Health Crisis. World Health Day 2013. Geneva, Switzerland: 2013. https://www.who.int/cardiovascular_diseases/publications/global_brief_hypertension/en/. Accessed on 01 September 2019
  • 2.NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet (London, England). 2017;389(10064):37–55. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Institute for Health Metrics and Evaluation (IHME). Findings from the Global Burden of Disease Study 2017. Seattle, WA: IHME; 2018. http://www.healthdata.org/sites/default/files/files/policy_report/2019/GBD_2017_Booklet.pdf. Accessed on October 2019.
  • 4.Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. Circulation. 2016;134(6):441–450. 10.1161/CIRCULATIONAHA.115.018912 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Lawes CM, Vander Hoorn S, Law MR, Elliott P, MacMahon S, Rodgers A. Blood pressure and the global burden of disease 2000. Part 1: estimates of blood pressure levels. Journal of hypertension. 2006;24(3):413–422. 10.1097/01.hjh.0000199801.72563.6f [DOI] [PubMed] [Google Scholar]
  • 6.Pereira M, Lunet N, Azevedo A, Barros H. Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. Journal of hypertension. 2009;27(5):963–975. 10.1097/hjh.0b013e3283282f65 [DOI] [PubMed] [Google Scholar]
  • 7.Institute for Public Health (IPH). National Health and Morbidity Survey 2015 (NHMS 2015). Vol. II: Non-Communicable Diseases, Risk Factors & Other Health Problems. 2015. http://www.moh.gov.my/moh/resources/nhmsreport2015vol2.pdf. Accessed on 12 September 2019.
  • 8.Asch SM, McGlynn EA, Hiatt L, Adams J, Hicks J, DeCristofaro A, et al. Quality of care for hypertension in the United States. BMC Cardiovasc Disord. 2005;5(1):1–9. 10.1186/1471-2261-5-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Chan SC, Chandramani T, Chen TY, Chong KN, Harbaksh S, Lee TW, et al. Audit of hypertension in general practice. The Medical journal of Malaysia. 2005;60(4):475–482. [PubMed] [Google Scholar]
  • 10.Kande C, Mash R. Improving the quality of care for patients with hypertension in Moshupa District, Botswana: quality improvement cycle. Afr J Prim Health Care Fam Med. 2014;6(1): 1–7. 10.4102/phcfm.v6i1.578 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Tong SF, Khoo EM, Nordin S, Teng CL, Lee VK, Zailinawati AH, et al. Process of care and prescribing practices for hypertension in public and private primary care clinics in Malaysia. Asia-Pacific journal of public health. 2012;24(5):764–775. 10.1177/1010539511402190 [DOI] [PubMed] [Google Scholar]
  • 12.Sivasampu S, Wahab YF, Ong SM, Ismail SA, Goh PP, Jeyaindran S. National Medical Care Statistics (NMCS) 2014. Kuala Lumpur: National Clinical Research Centre; 2016. Report No.: NCRC/HSU/2016.1
  • 13.Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med. 2002/11/07. 2002. November 11;162(20):2269–2276. 10.1001/archinte.162.20.2269 [DOI] [PubMed] [Google Scholar]
  • 14.Ab Majid NL, Omar MA, Khoo YY, Mahadir Naidu B, Ling Miaw Yn J, Rodzlan Hasani WS, et al. Prevalence, Awareness, Treatment and Control of hypertension in the Malaysian population: findings from the National Health and Morbidity Survey 2006–2015. Journal of human hypertension. 2018;32(8–9):617–624. 10.1038/s41371-018-0082-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Abdul-Razak S, Daher AM, Ramli AS, Ariffin F, Mazapuspavina MY, Ambigga KS, et al. Prevalence, awareness, treatment, control and socio demographic determinants of hypertension in Malaysian adults. BMC Public Health. 2016;16(1):351 10.1186/s12889-016-3008-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. Jama. 2013;310(9):959–968. 10.1001/jama.2013.184182 [DOI] [PubMed] [Google Scholar]
  • 17.Wong SLS, Lee PY, Ng CJ, Hanafi NS, Chia YC, Lai PS, et al. Are doctors assessing patients with hypertension appropriately at their initial presentation? Singapore medical journal. 2015;56(9):518–522. 10.11622/smedj.2015137 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Ministry of Health Malaysia. Clinical Practice Guidelines: Management of Hypertension 5th Edition Putrajaya: Ministry of Health Malaysia; 2018. [Google Scholar]
  • 19.WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet (London, England). 2004;363(9403):157–163. [DOI] [PubMed] [Google Scholar]
  • 20.StataCorp. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP; 2015. [Google Scholar]
  • 21.Cheong AT, Tong SF, Sazlina SG, Azah AS, Salmiah MS. Blood pressure control among hypertensive patients with and without diabetes mellitus in six public primary care clinics in Malaysia. Asia-Pacific journal of public health. 2015;27(2):Np580–5899. 10.1177/1010539513480232 [DOI] [PubMed] [Google Scholar]
  • 22.Ramli A, Miskan M, Ng K, Ambigga D, Nafiza M, Mazapuspavina M, et al. Prescribing of Antihypertensive Agents in Public Primary Care Clinics—is it in Accordance with Current Evidence? Malays Fam Physician. 2010;5(1):36–40. [PMC free article] [PubMed] [Google Scholar]
  • 23.Sivasampu S, Noh K, May Chien C. Quality and Costs of Primary Care (QUALICOPC)- Malaysia Phase 1 Report. Kuala Lumpur: National Clinical Research Centre; 2015. [Google Scholar]
  • 24.National Specialist Register of Malaysia. Recognized Postgraduate Qualifications in Family Medicine 2019 [cited 2019 15 October]. https://www.nsr.org.my/qualifications1.html#FAMILYMEDICINE.
  • 25.Ministry of Health Malaysia. Malaysian Statistics on Medicines (MSOM) 2011–2014. Malaysia: Pharmaceutical Services Division; 2017. https://www.pharmacy.gov.my/v2/sites/default/files/document-upload/malaysian-statistics-medicines-2011-2014.pdf. Accessed on 29 September 2019. [Google Scholar]
  • 26.Mustapha F, Omar Z, Mihat O, Md Noh K, Hassan N, Abu Bakar R, et al. Addressing non-communicable diseases in Malaysia: an integrative process of systems and community. BMC Public Health. 2014;14 Suppl 2:S4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Ministry of Health Malaysia. Malaysia Ministry of Health Medicines Formulary; 2017. http://www.pharmacy.gov.my/v2/ms/apps/fukkm. Accessed on 29 September 2019.
  • 28.Ahmad N, Khan AH, Khan I, Khan A, Atif M. Doctor's Knowledge of Hypertension Guidelines Recommendations Reflected in Their Practice. International Journal of Hypertension. 2018;2018:1–11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. Jama. 1999;282(15):1458–1465. 10.1001/jama.282.15.1458 [DOI] [PubMed] [Google Scholar]
  • 30.Chan GC, Ghazali O, Khoo EM. Management of type 2 diabetes mellitus: is it in accordance with the guidelines? The Medical journal of Malaysia. 2005;60(5):578–584. [PubMed] [Google Scholar]
  • 31.Wagner EH, Glasgow RE, Davis C, Bonomi AE, Provost L, McCulloch D, et al. Quality improvement in chronic illness care: a collaborative approach. The Joint Commission journal on quality improvement. 2001;27(2):63–80. 10.1016/s1070-3241(01)27007-2 [DOI] [PubMed] [Google Scholar]
  • 32.Cole JA, Smith SM, Hart N, Cupples ME. Systematic review of the effect of diet and exercise lifestyle interventions in the secondary prevention of coronary heart disease. Cardiology research and practice. 2010;2011:1–25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Yarnall KS, Ostbye T, Krause KM, Pollak KI, Gradison M, Michener JL. Family physicians as team leaders: "time" to share the care. Preventing chronic disease. 2009;6(2):1–6. [PMC free article] [PubMed] [Google Scholar]
  • 34.Ministry of Health. Clinical Practice Guidelines: Management of Type 2 Diabetes Mellitus 5th Edition Putrajaya: Ministry of Health Malaysia; 2015. [Google Scholar]
  • 35.Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. The New England journal of medicine. 2012;366(13):1227–1239. 10.1056/NEJMra1005073 [DOI] [PubMed] [Google Scholar]
  • 36.Erden S, Bicakci E. Hypertensive retinopathy: incidence, risk factors, and comorbidities. Clinical and experimental hypertension (New York, NY: 1993). 2012;34(6):397–401. [DOI] [PubMed] [Google Scholar]
  • 37.Fagard RH, Cornelissen VA. Effect of exercise on blood pressure control in hypertensive patients. European journal of cardiovascular prevention and rehabilitation: official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology. 2007;14(1):12–17. [DOI] [PubMed] [Google Scholar]
  • 38.Bouchard C, Depres JP, Tremblay A. Exercise and obesity. Obesity research. 1993;1(2):133–147. 10.1002/j.1550-8528.1993.tb00603.x [DOI] [PubMed] [Google Scholar]
  • 39.Dong OM. Excessive dietary sodium intake and elevated blood pressure: a review of current prevention and management strategies and the emerging role of pharmaconutrigenetics. BMJ Nutrition, Prevention & Health. 2018; 0: 1–10. https://nutrition.bmj.com/content/bmjnph/early/2018/10/05/bmjnph-2018-000004.full.pdf. Accessed on 05 September 2019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009/03/11. 2009. March;122(3):290–300. 10.1016/j.amjmed.2008.09.038 [DOI] [PubMed] [Google Scholar]
  • 41.Gimpel N, Schoj V, Rubinstein A. Quality management of hypertension in primary care: Do physicians treat patients' blood pressure level or cardiovascular risk? Quality in Primary Care. 2006;14:211–217. [Google Scholar]

Decision Letter 0

Anderson Saranz Zago

1 Apr 2020

PONE-D-19-33878

Quality of hypertension management in public primary care clinics in Malaysia: an update

PLOS ONE

Dear Miss Teh,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by May 16 2020 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Anderson Saranz Zago, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (if provided):

According to the opinion of the reviewers, the manuscript brings an interesting subject, however, it needs to be reviewed on several topics. After all these changes, the authors can resubmit the manuscript for a new evaluation.

Sincerely

Anderson Saranz Zago, PhD.

Academic editor

Journal Requirements:

When submitting your revision, we need you to address these additional requirements:

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf and http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please state the date upon which the data used in this survey was accessed. In addition, please refer to any post-hoc corrections to correct for multiple comparisons during your statistical analyses. If these were not performed please justify the reasons. Please refer to our statistical reporting guidelines for assistance (https://journals.plos.org/plosone/s/submission-guidelines.#loc-statistical-reporting).

3. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This article investigated the management of hypertensive patients in primary care clinics in Malaysia, based upon data from 13,784 medical records. Although the study is sound and data are valuable, some issues should be reviewed.

Introduction

1) The authors provide general information about BP management worldwide and in developing countries, but the central problem remained unclear. What is the central point to be demonstrated and why? In short, the problem and purpose of the work should be clearly defined.

Methods

2) It seems that the only measures of BP management were "types of counselling provided as well as the prescribed antihypertensive medications". How the types of counselling have been effectively assessed and what about the quantity and quality of these interventions? As for the medications, what information has been extracted (type, dose etc). Please detail these aspects.

3) What independent comparisons have been performed through the t-tests and Mann-Whitney tests? What were the processes of care and prescribing patterns inserted in the multivariate analysis?

4) "Complete case analysis was performed for the regression" - did the authors considered the use of intention to treat analysis? Information about the drop outs within the more than 13,000 cases would be useful. How many patients did not comply to the prescribed treatament or failed to perform reasssessment during the study?

Results

1) Overall, although interesting, data seem to reproduce information extensively acknowledged in the literature. This is an important issue to be commented by the authors. Moreover, some aspects must be further clarified. For instance, how "Inappropriate choice of antihypertensive agents" was defined?

2) Only 2.5% of patients received counselling in regards to lifestyle modifications, which seems to be a very small proportion to allow statements about the effectiveness of these procedures to improve BP control. Moreover, information about the characteristics of patients that received this type of counselling would be useful to a better understanding of these findings.

3) Finally, please explain why to take two or more antihypertensive agents was inversely associated with BP management - is this due to the treatment or to the fact that those patients had higher BP levels. The way the text is written may lead to misinterpretation of these findings.

Discussion

1) The statement that the study reported "on the quality of indicated care processes received by hypertensive patients" poses problem. The quality of counselling and other procedures have been not assessed, but only their descriptive characteristics.

2) "The possible factors contributing to suboptimal control of hypertension could be due to patient-related factors including patients’ lifestyle and other risk factors, difficulties in adherence to prescribed regimens, limited access to care and lack of knowledge about seriousness of hypertension". This is true and significangtly limits the interpretation of the presented findings. Additional information on these features should be provided. The use of intention to treat approach could also enhance the strength of the data and should be considered by the authors, or at least information on drop outs should be provided.

3) Although interesting as a text, most part of the Discussion seems to be highly speculative (please refer to lines 242 to 260).

4) The authors seemed to assume the physical activity counselling has been effectively resulted in actual practice - any information on this?

Reviewer #2: The authors managed to demonstrate how the number of hypertensive patients worldwide is growing, and the control of blood pressure in countries still leaves a desire. Therefore, it has a high relevance in the study of evaluating the quality of care in primary care clinics in Malaysia. The article shows solid results, however some corrections are needed.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: review on PLOS ONE manuscript.docx

Decision Letter 1

Anderson Saranz Zago

11 Jun 2020

PONE-D-19-33878R1

Quality of hypertension management in public primary care clinics in Malaysia: an update

PLOS ONE

Dear Dr. Xin Rou Teh

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

As you can see, just one reviewer asked for minor revision.

Please submit your revised manuscript by june 21, 2020. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Anderson Saranz Zago, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (if provided):

According to the opinion of the one reviewers, the manuscript still have a few points to be adressed. After all these changes, the authors can resubmit the manuscript for a new evaluation.

Sincerely

Anderson Saranz Zago, PhD.

Academic editor

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The manuscript has substantially improved after review and I commend the authors for their effort to address my comments. However, I would make a last suggestion, given the changes made in the Introduction section.

Please rephrase the new hypothesis in lines 85-86: “We hypothesized that hypertensive patients who received care for hypertension were associated with better BP control”. This seems quite obvious as an hypothetical approach and does not reflect the main purpose or results of your study.

In my opinion, the main contribution of this cross-section study is the description of the characteristics of care processes in a substantial amount of public health clinics. Moreover, the odds of specific intervention strategies to produce effective results in terms of BP management were analyzed through logistic regression – this is an important aspect, which has nothing to do with the presented hypothesis.

As you state in lines 165-166, “this was a cross sectional study on hypertension management” and its strong points should be put in value when writing the objectives and related hypotheses.

Reviewer #2: The authors accepted and agreed with the suggestions previously made correctly, provided all the data that support the conclusion of the present study. The statistical analyzes met the proposal of the study, and presented interesting results.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Paulo Farinatti

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: review on PLOS ONE manuscript.docx

PLoS One. 2020 Aug 11;15(8):e0237083. doi: 10.1371/journal.pone.0237083.r004

Author response to Decision Letter 1


11 Jun 2020

Dear Editor and Reviewer #1,

The current study aimed to assess the process of care for hypertension management and the association between process of care and blood pressure control in primary care clinics in Malaysia.

INTRODUCTION

The authors were asked to rephrase the hypothesis in lines 85-86: “We hypothesized that hypertensive patients who received care for hypertension were associated with better BP control”. The reviewer felt that it did not reflect the main purpose or results of the study. The authors agree with the reviewer and have omitted the hypothetical statement. It now reads:

Introduction, Line 78-86, page 5:

“In Malaysia, improvement in process of care has been undertaken over the years with better establishment of non-communicable disease care such chronic care concepts, diabetic registry, nurse educator and better range of antihypertensive medication. Although there were some evaluations on hypertension, process of care evaluation was last done 10 years ago [11]. Most of the evaluations on hypertensive care focused on the burden of hypertension in the Malaysian population [14–16]. Similarly, evaluations on process of care and BP control in low- and middle-income countries are scarce. Therefore, we aimed to evaluate the current process of care for hypertension management as well as to explore the association between process of care and BP control among hypertensive patients in public primary care clinics in Malaysia.”

Attachment

Submitted filename: Response to Reviewer.docx

Decision Letter 2

Anderson Saranz Zago

21 Jul 2020

Quality of hypertension management in public primary care clinics in Malaysia: an update

PONE-D-19-33878R2

Dear Dr. Xin Rou Teh

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Anderson Saranz Zago, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

After resubmission, it can be observed that all comments were addressed. So, I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations!

Sincerely

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Paulo Farinatti

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: review on PLOS ONE manuscript.docx

    Attachment

    Submitted filename: Response to Reviewers.docx

    Attachment

    Submitted filename: review on PLOS ONE manuscript.docx

    Attachment

    Submitted filename: Response to Reviewer.docx

    Data Availability Statement

    All relevant data are provided within the manuscript. Individual level data cannot be made publicly available due to ethical and patient confidentiality restrictions. The data collected within this study is managed in accordance with the Personal Data Protection Act in Malaysia and is subject to ethical restrictions under the Medical Research and Ethics Committee, Ministry of Health Malaysia. Data is available on request and interested researchers may address data access requests to the Institute for Clinical Research at contact@crc.gov.my.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES